Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028

Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028

The global ophthalmic drugs market was valued at $23bn in 2017. The market was dominated by the Retinal Disorder drug submarket which held 39.1% of the global ophthalmic drugs market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 223-page report you will receive 83 tables and 71 figures– all unavailable elsewhere.

The 223-page report provides clear detailed insight into the top ophthalmic drugs manufacturers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global ophthalmic drugs market revenue forecasts from 2018-2028
  • Global ophthalmic drugs market revenue orecasts from 2018-2028, by submarket:
  • Retinal Disorder Drugs
  • Allergic, Inflammatory & Infective Drugs
  • Glaucoma Drugs
  • Dry Eye Drugs
  • Other Ophthalmic Drugs
  • Revenue forecasts from 2018-2028 of the leading ophthalmic drugs:
  • Alphagan
  • Avastin
  • Azopt
  • Eylea
  • Lucentis
  • Lumigan & Ganfort
  • Other Ophthalmic Drugs
  • Restasis
  • Vigamix
  • Xalatan/Xalacom
  • Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:
  • Acucela
  • Akorn
  • Alimera Sciences
  • Allergan
  • Amakem
  • Bayer
  • Chengdu Kanghong
  • EyeGate Pharmaceuticals
  • Gene Signal
  • Icon Biosciences
  • MacuCLEAR
  • Neurotech
  • Novartis
  • Omeros
  • Ophthotech
  • Otsuka Pharmaceutical
  • Pfizer
  • pSivida Corp.
  • Regeneron
  • Roche
  • Santen
  • Senju
  • Shire
  • ThromboGenics
  • Valeant
  • Our report provides an overview, revenue forecast from 2018-2028 of the ophthalmic drugs segment, revenue forecast from 2018-2028 of the leading drugs, product pipeline and SWOT Analysis, for these companies:
  • Akorn
  • Alcon
  • Allergan
  • Bausch & Lomb
  • Bayer
  • Novartis
  • Pfizer
  • Regeneron
  • Roche
  • Santen
  • Senju
  • Valeant
  • Our report provides these Qualitative Analysis:
  • Drivers and Restraints of the Global Ophthalmic Drugs market
  • SWOT Analysis of selected leading companies
  • Porter’s Five Forces Analysis of the Global Ophthalmic Drugs Market
Visiongain’s study is intended for anyone requiring commercial analyses for the ophthalmic drugs market. You find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1. Report Overview
1.1 Global Ophthalmic Drugs Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: Very Brief Overview
2.2 The Global Burden of Eye Disease
2.3 Ophthalmic Drugs: Market Segmentation
2.4 Glaucoma: the ‘Silent Thief of Sight’
2.4.1 A Classification of Glaucoma
2.4.2 Risk Factors for Glaucoma
2.4.3 Diagnosis of Glaucoma
2.4.4 Drug Treatment of Glaucoma
2.4.5 Laser Treatment and Surgery for Glaucoma
2.5 Age-Related Macular Degeneration (AMD)
2.5.1 Dry (Non-Exudative) AMD
2.5.2 Wet (Exudative) AMD
2.5.3 Risk Factors for AMD
2.5.4 Diagnosis of AMD
2.5.5 Treatment of AMD
2.6 Diabetic Retinopathy (DR)
2.6.1 Diagnosis of Diabetic Retinopathy
2.6.2 Treatment of Diabetic Retinopathy
2.7 Ocular Allergy and Allergic Conjunctivitis
2.7.1 Diagnosis of Ocular Allergy
2.7.2 Treatment of Ocular Allergy
2.8 Ocular Inflammatory Disease
2.8.1 Treatment of Ocular Inflammatory Disease
2.9 Eye Infections
2.9.1 Treatment of Eye Infections
2.10 Dry Eye Syndrome
2.10.1 Treatment of Dry Eye Syndrome
2.11 Phases of Clinical Trials
3. Ophthalmic Drugs: World Market 2018-2028
3.1 The World Ophthalmic Drugs Market in 2018
3.2 World Ophthalmic Drugs Market: Sales Forecast 2018-2028
3.3 Leading Ophthalmic Drugs
3.4 Leading Companies in the Ophthalmic Drugs Market
3.4.1 Top 25 Ophthalmic Drug Manufacturers
3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2018-2028
3.5.1 Retinal Disorders Drugs Market: Sales Forecast 2018-2028
3.5.2 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2018-2028
3.5.3 Glaucoma Drugs Market: Sales Forecast 2018-2028
3.5.4 Dry Eye Drugs Market: Sales Forecast 2018-2028
3.5.5 Other Ophthalmic Drugs Market: Sales Forecast 2018-2028
3.6 How Will Market Shares Change to 2028?
3.7 World Ophthalmic Drugs Market: Drivers and Restraints 2018-2028
3.7.1 World Ophthalmic Drugs Market: Analysis of Drivers
3.7.2 World Ophthalmic Drugs Market: Analysis of Restraints
4. Leading US Ophthalmic Drug Manufacturers 2018-2028
4.1 Allergan Overview
4.1.1 Allergan: Ophthalmic Product Portfolio
4.1.2 Allergan: Late Stage Ophthalmic Product Pipeline
4.1.3 Allergan: Ophthalmic Revenue Forecast 2018-2028
4.1.4 Allergan: SWOT Analysis
4.2 Pfizer Overview
4.2.1 Pfizer: Ophthalmic Product Portfolio
4.2.2 Pfizer: Ophthalmic Product Pipeline
4.2.3 Pfizer: Revenue Forecast 2018-2028
4.2.4 Pfizer: SWOT Analysis
4.3 Regeneron Overview
4.3.1 Regeneron: Ophthalmic Product Portfolio
4.3.2 Regeneron: Ophthalmic Product Pipeline
4.3.3 Regeneron: Revenue Forecast 2018-2028
4.3.4 FDA Approves Zaltrap (aflibercept)
4.3.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
4.3.6 Regeneron: SWOT Analysis
4.4 Akorn Overview
4.4.1 Akorn: Ophthalmic Product Portfolio
4.4.2 Akorn: Revenue Forecast 2018-2028
4.4.3 Akorn: SWOT Analysis
5. Leading European Ophthalmic Drug Manufacturers 2018-2028
5.1 Bayer Overview
5.1.1 Bayer: Ophthalmic Product Pipeline
5.1.2 Eylea: non-US Sales Forecast 2018-2028
5.1.3 Bayer: Revenue Forecast 2018-2028
5.2 Novartis (including Alcon) Overview
5.2.1 Novartis: Ophthalmic Product Portfolio
5.2.2 Novartis: Ophthalmic Product Pipeline
5.2.3 Novartis: Revenue Forecast 2018-2028
5.2.4 Novartis: SWOT Analysis
5.3 Roche Overview
5.3.1 Roche: Ophthalmic Product Portfolio
5.3.2 Roche: Ophthalmic Product Pipeline
5.3.3 Roche: Revenue Forecast 2018-2028
5.3.4 Roche: SWOT Analysis
6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers 2018-2028
6.1 Santen Overview
6.1.1 Santen: Ophthalmic Product Portfolio
6.1.2 Santen: Ophthalmic Product Pipeline
6.1.3 Santen: Revenue Forecast 2018-2028
6.1.4 Santen: SWOT Analysis
6.2 Senju Overview
6.2.1 Senju: Ophthalmic Product Portfolio
6.2.2 Senju: Ophthalmic Product Pipeline
6.2.3 Senju: Revenue Forecast 2018-2028
6.2.4 Senju: SWOT Analysis
6.3 Valeant Overview
6.3.1 Valeant: Ophthalmic Product Portfolio
6.3.2 Valeant: Ophthalmic Product Pipeline
6.3.3 Valeant: Revenue Forecast 2018-2028
6.3.4 Valeant: SWOT Analysis
7. Emerging Ophthalmic Drug Manufacturers in 2017
7.1 Companies with Small Ophthalmic Portfolios and Promising Pipeline Candidates, 2017
7.2 Acucela
7.3 Aerie Pharmaceuticals
7.4 Aerpio Therapeutics: Developing AKB 9778
7.5 Alimera Sciences
7.5.1 Iluvien: Increasing Geographical Reach and Increasing Sales
7.5.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD
7.6 Amakem
7.7 Ampio Pharmaceuticals
7.8 Chengdu Kanghong Pharmaceutical
7.9 Eleven Biotherapeutics
7.10 EyeGate Pharmaceuticals
7.11 Gene Signal
7.11.1 Aganirsen: Preventing Corneal Graft Rejection
7.12 Icon Bioscience
7.13 MacuCLEAR
7.13.1 MC 1101: a Potential Therapy for Dry AMD
7.14 Neurotech
7.15 Omeros
7.16 OphthaliX (Can-Fite BioPharma)
7.17 Ophthotech
7.17.1 Fovista: Potential Game-Changer in AMD
7.17.2 Fovista: Significant Improvement on Lucentis in Phase II Trials
7.17.3 Zimura: Complement C5 Inhibitor
7.18 Otsuka Pharmaceutical
7.19 pSivida Corp.
7.20 RXi Pharmaceuticals: Will Bevasiranib Resume Development?
7.21 Shire
7.21.1 Lifitegrast (SHP606) for Dry Eye
7.21.2 Premiplex (SHP607): Preventing Retinopathy of Prematurity
7.22 ThromboGenics
7.22.1 Jetrea (ocriplasmin)
7.22.2 ThromboGgenics: Leading Diabetic Eye Disease Pipeline
8. Qualitative Analysis of the Ophthalmic Drugs Market 2018-2028
8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market
8.1.1 Rivalry Among Competitors [Medium]
8.1.2 Threat of New Entrants [Low]
8.1.3 Power of Suppliers [Low]
8.1.4 Power of Buyers [Medium]
8.1.5 Threat of Substitutes [Medium]
9. Conclusions
9.1 Ophthalmic Pharmaceuticals: A Growing Niche Market
9.2 The World Ophthalmic Drugs Market in 2017
9.2.1 Leading Ophthalmic Drugs Market Segments
9.2.2 Leading Ophthalmic Drugs
9.2.3 Leading Ophthalmic Drugs Companies
9.3 World Ophthalmic Drugs Market Forecast 2018-2028
9.4 The Future of the Ophthalmic Drugs Market?
9.4.1 Increasing Revenue Concentration among Specialist Companies
9.4.2 The Rise of Generics
9.4.3 Small Companies Can Have a Big Impact
9.4.4 What Will Succeed in the Ophthalmic Drugs Market?
Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Tables
Table 2.1 ICD 10 Classification of Visual Impairment, 2015
Table 2.2 Drug Treatments for Glaucoma, 2017
Table 2.3 Drug Treatments for AMD, 2017
Table 2.4 Drug Treatments for Ocular Allergy, 2017
Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2017
Table 2.6 Selected Drug Treatments for Eye Infections, 2017
Table 2.7 Clinical Trial Phases
Table 3.1 World Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2017
Table 3.2 World Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2018-2028
Table 3.3 Top 10 Ophthalmic Drugs: Revenue ($m), Market Share (%), Rank, Active Ingredient and Manufacturer, 2017
Table 3.4 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Market Share (%), 2017
Table 3.5 Top 25 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Leading Pipeline Products, 2017
Table 3.6 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2017-2028
Table 3.7 Retinal Disorders Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2028
Table 3.8 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 3.9 Glaucoma Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2028
Table 3.10 Dry Eye Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2028
Table 3.11 Other Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2028
Table 3.12 Market Shares (%) of the Ophthalmic Drugs Market by Segment, 2017, 2023 and 2028
Table 4.1 Allergan: Overview, 2017
Table 4.2 Allergan: Ophthalmic Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
Table 4.3 Allergan: Restasis Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.4 Allergan: Lumigan and Ganfort Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.5 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.6 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.7 Allergan: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 4.8 Allergan: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 4.9 Pfizer: Overview, 2017
Table 4.10 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.11 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.12 Pfizer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 4.13 Pfizer: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 4.14 Regeneron: Overview, 2017
Table 4.15 Regeneron: Eylea Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.16 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.17 Regeneron: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 4.18 Regeneron: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 4.19 Akorn: Overview, 2017
Table 4.20 Akorn: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.21 Akorn: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 4.22 Akorn: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 5.1 Bayer: Overview, 2017
Table 5.2 Bayer: Eylea Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 5.3 Bayer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 5.4 Bayer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 5.5 Novartis: Overview, 2017
Table 5.6 Novartis: Lucentis Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 5.7 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 5.8 Novartis: Vigamox Revenue ($m), AGR (%) and CAGR(%), 2017-2028
Table 5.9 Novartis: Azopt Revenue ($m), AGR (%) and CAGR(%), 2017-2028
Table 5.11 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 5.12 Novartis: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 5.13 Novartis: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 5.14 Roche: Overview, 2017
Table 5.15 Roche: Lucentis Revenue ($m), AGR (%) and CAGR(%), 2017-2028
Table 5.16 Roche: Avastin Ophthalmic Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 5.17 Roche: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 5.18 Roche: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 5.19 Roche: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 6.1 Santen: Overview, 2017
Table 6.2 Santen: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Date, Region, 2017
Table 6.3 Santen: Eylea Revenue ($m), AGR (%) and CAGR(%), 2017-2028
Table 6.4 Santen: Hyalein Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.5 Santen: Cosopt Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.6 Santen: Tapros/Taflotan Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.7 Santen: Diquas Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.8 Santen: Cravit Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.9 Santen: Alesion Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.10 Santen: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.11 Santen: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 6.12 Santen: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 6.13 Senju: Overview, 2017
Table 6.14 Senju: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Year, 2017
Table 6.15 Senju: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.16 Senju: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 6.17 Senju: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 6.18 Valeant: Overview, 2017
Table 6.19 Valeant: Lotemax Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.20 Valeant: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.21 Valeant: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 6.22 Valeant: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 7.1 Otsuka Pharmaceutical: Overview of Ophthalmic Drug Pipelines, Drug Type, Indication, Country
Table 9.1 Leading Ophthalmic Drugs Manufacturers: Revenues ($m), Market Share (%), 2018
List of Figures
Figure 1.1 Global Causes of Visual Impairment (% of cases), 2017
Figure 1.2 World 65+ Population Forecast: Size (millions), CAGR (%), by National Market, 2015 and 2026
Figure 1.3 Global Ophthalmic Drugs Market Segmentation Overview, 2017
Figure 2.1 Estimated Global Blindness and Visual Impairment (% of people), 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook